RNS Number : 7055Z
Oxford Biomedica PLC
08 April 2026
OXB
Grant of Awards
Oxford, UK - 08 April 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 07 April 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company's 2024 Long Term Incentive Plan ("LTIP"), including Restricted Share Units ("RSU") and the Company's 2024 Deferred Bonus Plan ("DBP").
As detailed in the recently published 2025 Directors' Remuneration Report:-
Re-instated LTIP awards: the LTIP grants in respect of 2024 and 2025, detailed below, reinstate the originally intended grant level for Dr. Frank Mathias and Dr. Lucinda Crabtree's 2024 and 2025 LTIP awards. The 2024 and 2025 LTIP awards were scaled back, primarily to manage the headroom available under the OXB share plans. The re-instatement honors the terms on which Dr. Mathias and Dr. Crabtree were recruited and reflects the Company's performance detailed in the 2025 Annual report and accounts. The re-instated LTIP awards remain subject to the original performance conditions and post-vesting holding periods, ensuring that the vesting of the awards is subject to the sustained strong performance of the business.
LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company's Directors' Remuneration Report for 2025.
Type
Name of individual
Title
Number of share options granted
LTIP - Grant in respect of 2026
Dr. Frank Mathias
Chief Executive Officer
478,119
LTIP - Grant in respect of 2025
46,195
LTIP - Grant in respect of 2024
43,790
2026 DBP
Dr. Frank Mathias
Chief Executive Officer
71,891
LTIP - Grant in respect of 2026
Dr. Lucinda Crabtree
Chief Financial Officer
156,884
LTIP - Grant in respect of 2025
26,526
LTIP - Grant in respect of 2024
12,876
2026 DBP
Dr. Lucinda Crabtree
Chief Financial Officer
47,179
LTIP - Grant in respect of 2026
Natalie Walter
Chief Legal Officer and Group Company Secretary
75,479
2026 DBP
Natalie Walter
Chief Legal Officer and Group Company Secretary
12,459
LTIP - Grant in respect of 2026
Dr. Kyriacos Mitrophanous
Chief Innovation Officer
72,391
2026 DBP
Dr. Kyriacos Mitrophanous
Chief Innovation Officer
10,841
LTIP - Grant in respect of 2026
Lisa Doman
Chief People Officer
69,992
2026 DBP
Lisa Doman
Chief People Officer
10,629
LTIP - Grant in respect of 2026
Dr. Sébastien Ribault
Chief Business Officer
107,102
2026 DBP
Dr. Sébastien Ribault
Chief Business Officer
14,908
LTIP - Grant in respect of 2026
Mark Caswell
Site Head, UK Operations
49,431
2026 LTIP RSU
Dr. Sabine Sydow
Chief of Staff
7,036
2026 LTIP RSU
Dr. Melanie Kearney
Global Head of Quality
12,711
2026 LTIP RSU
John Foy
Site Head, Durham Operations
12,380
2026 LTIP RSU
Stéphanie Colloud
Site Head and General Manager of France Operations
10,357
2026 LTIP RSU
Kathleen Miller
Head of Human Resources (and acting Interim Site Head, Bedford)
12,628
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Frank Mathias
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
Nil LTIP awards over 46,195 shares in total Nil LTIP awards over 43,790 shares in total Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Frank Mathias
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
71,891
h)
Aggregated information
- Aggregated volume
DBP awards granted over 71,891 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Lucinda Crabtree
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
Nil LTIP awards over 26,526 shares in total Nil LTIP awards over 12,876 shares in total Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Lucinda Crabtree
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
47,179
h)
Aggregated information
- Aggregated volume
DBP awards granted over 47,179 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Legal Officer and Group Company Secretary
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Natalie Walter
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
75,479
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 75,479 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Legal Officer and Group Company Secretary
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Natalie Walter
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
12,459
h)
Aggregated information
- Aggregated volume
DBP awards granted over 12,459 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Business Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
SébastienRibault
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
107,102
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 107,102 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Business Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
SébastienRibault
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
14,908
h)
Aggregated information
- Aggregated volume
DBP awards granted over 14,908 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief People Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Lisa Doman
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
69,992
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 69,992 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief People Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Lisa Doman
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
10,629
h)
Aggregated information
- Aggregated volume
DBP awards granted over 10,629 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Innovation Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Kyriacos Mitrophanous
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
72,391
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 72,391 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Innovation Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Kyriacos Mitrophanous
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)
Price(s) and volumes(s)
Award
Price
Volume
DBP grant in respect of 2026
Nil
10,841
h)
Aggregated information
- Aggregated volume
DBP awards granted over 10,841 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Site Head, UK Operations
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Mark Caswell
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
49,431
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 49,431 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief of Staff
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Sabine Sydow
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP RSU grant in respect of 2026
Nil
7,036
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 7,036 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Global Head of Quality
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Melanie Kearney
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP RSU grant in respect of 2026
Nil
12,711
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,711 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Site Head, Durham Operations
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
John Foy
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP RSU grant in respect of 2026
Nil
12,380
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,380 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Site Head and General Manager of France Operations
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Stephanie Colloud
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP RSU grant in respect of 2026
Nil
10,357
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 10,357 shares in total
- Price
Nil
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Head of Human Resources (and acting Interim Site Head, Bedford)
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Kathleen Miller
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-04-07
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP - British Pound
f)
Nature of the transaction
Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP RSU grant in respect of 2026
Nil
12,628
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,628 shares in total
- Price
Nil
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBLGDSUBGDGLI
